Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMXT 1501 in healthy volunteers
NCT03077477Phase 1Withdrawn
- Sponsor
- Aminex Therapeutics
- Start
- Jun 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMXT-1501 in solid tumor (5 arms), sponsored by Aminex Therapeutics. Primary endpoints: Maximum Feasible Dose at 6 months, Area Under the Curve at 6 months and 3 more. Planned start Jun 2018; status: withdrawn.
02
Drugs
AMXT-1501
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03077477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03077477.